
    
      This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo controlled,
      parallel-group study to evaluate the efficacy and safety of 2 intravenous (IV) treatment
      regimens in adult participants with chronic, moderately-to-severely active SLE with an
      inadequate response to SOC SLE. The investigational product (anifrolumab or placebo) will be
      administered as a fixed dose every 4 weeks (28 days) for a total of 13 doses.
    
  